July 2012

Life sciences


The Canadian Institutes of Health Research has ranked no 1 a drug treatment developed at Université Laval

CIHR has ranked MicselonTM as the best translational life science project in Canada (no 1 among more than twenty projects). Preclinical data strongly suggest that MicselonTM is ideally suited to become a first-in-class therapy against urinary retention problems and related health problems (urinary tract infections, sepsis, etc.) in patients chronically suffering of spinal cord injury.


Medicago Completes the Production of More Than Ten Million Doses of Vaccine in One Month

Medicago Completes the Production of More Than Ten Million Doses of Vaccine in One Month

Medicago announced the successful completion of a key milestone under an agreement with the Defense Advanced Research Projects Agency (DARPA). The milestone was the production of at least 10 million doses of H1N1 VLP influenza vaccine candidate in one month ("rapid fire test").   This rapid fire test was conducted at Medicago's facility in Durham, North Carolina.


DiagnoCure Issues Statement on Acquisition of Gen‐Probe by Hologic

DiagnoCure Issues Statement on Acquisition of Gen‐Probe by Hologic

The acquisition, announced yesterday, is being viewed favorably by DiagnoCure management who see an opportunity for the combined companies to put additional resources behind the marketing of the PROGENSA® PCA3 prostate cancer test. “Our expectation is that the combined entity, with an expanded footprint within cancer diagnostics, will be in an even stronger position to bring PROGENSA PCA3 to physicians and patients” stated Dr. Yves Fradet, President and Chief Medical Officer of DiagnoCure.


Medicago pledges $4-million plant

Quebec City-based drug researcher Medicago Inc. said Monday it is pushing ahead with a $4-million pilot production plant for non-flu vaccine products. It will be located in Quebec City.


A revolutionary innovation in the military sector

Mr. Stéphane Bédard, CEO of the Quebec City company B-Temia, has been interviewed for Vanguard Magazine, a publication specialized in defence and security.


European Life Science Journal : Quebec is the rising star in Canada

Québec is the place to do business, especially in the life sciences, explains Carl Viel, President and CEO of Québec International. (page 39) 


DiagnoCure : PCA3 Test Featured at American Urological Association Meeting

DiagnoCure reports that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA. The value of PCA3 testing was highlighted during a debate on the new USPSFT recommendation on prostate cancer screening. PCA3 testing was the topic of 14 presentations during the meeting.


Aeterna Zentaris: Article on Perifosine as Potential Novel Approach to the Treatment of Mesothelioma Published in Plos One

 Aeterna Zentaris announced that an article published in the May 2012 issue of Plos One, outlines a novel mechanism of action of the Company's oral anti-cancer compound, perifosine, which could provide a rationale for a novel approach to the treatment of Malignant Pleural Mesothelioma, an aggressive type of cancer associated with exposure to asbestos. The article is available at www.plosone.org. Plos One is an international, peer reviewed on-line publication.


Aeterna Zentaris: Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology

Aeterna Zentaris announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology. The article outlines the safety profile and encouraging clinical activity of perifosine when combined with lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma. 


Vaccine Gardens - Medicago’s growth is steady

To subdue a fast-moving pandemic, governments need fast moving scientists and labs and manufacturing facilities able to churn out vaccines targeted to the deadly viruses. Speedy delivery of vaccines is exactly the business of Medicago, a Quebec-based biotech with manufacturing facilities in Quebec and North Carolina.